In late September 2025, China's ambassador to Nigeria announced a plan for Chinese companies to build an insulin-production facility in the West African nation. That announcement follows a string of deals between Nigerian and Chinese companies to construct facilities for manufacturing antimalarials and antiretrovirals. Although these agreements are made between corporations, they are part of China's Health Silk Road (HSR) strategy. The HSR is one element of the Belt and Road Initiative (BRI).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile